Mosaic ImmunoEngineering’s latest 10-Q reveals termination of its exclusive cowpea mosaic virus (CPMV) licensing, a foundational technology that had underpinned the company’s immunotherapy pipeline. This pivotal change necessitates a strategic repositioning focused on acquiring new clinical-stage assets and leveraging proprietary AI technologies to identify innovative immunotherapy combinations. While the company pursues opportunistic licensing deals, notably with Oncotelic Therapeutics for necroptosis vascular disruptive agents, it faces substantial capital constraints and regulatory hurdles characteristic of early-stage biotech. Its business model remains centered on outsourced manufacturing and research-driven pipeline development without commercial revenues. The path forward hinges on securing additional technologies and financing to sustain operations.